- Trump rallies at site of failed assassination: 'Never quit'
- Too hot by day, Dubai's floodlit beaches are packed at night
- Is music finally reckoning with #MeToo?
- Fans hail Trump's 'guts' as he returns to site of rally shooting
- Lebanon state media says 'very violent' Israeli strikes hit south Beirut
- Guardians maul Tigers, miracle Mets rally in MLB series openers
- Lebanon state media says Israeli strikes hit south Beirut
- Miami on track for MLS record points after win in Toronto
- Madrid beat Villarreal but Carvajal suffers knee injury
- Madrid beat Villarreal to move level with Liga leaders Barcelona
- Monaco take top spot in Ligue 1 with win at Rennes
- French rugby player on rape charge whistled but 'serene' on return
- Madrid beat Villarreal to level Liga leaders Barca
- Thuram treble fires Inter past Torino and up to second
- 'Fight': defiant Trump jets in to site of rally shooting
- Toddler among 3 dead in migrant Channel crossings
- Mexico City's new mayor sworn in with pledges on water, housing
- Israel on alert ahead of Hamas attack anniversary
- Guardians maul Tigers in MLB playoff series opener
- Macron criticises Israel on Gaza, Lebanon operations
- French rugby player whistled but 'serene' on return amid ongoing rape case
- Kovacic stars as Man City sink Fulham to get title bid back on track
- Retegui hat-trick fires five-star Atalanta to hammering of Genoa
- Heavyweights Australia, England off to World Cup winning starts
- Visiting UN refugee agency chief decries 'terrible crisis' in Lebanon
- Spinners come to party as England defeat Bangladesh at T20 World Cup
- Search continues for missing in deadly Bosnia floods
- Man City sink Fulham to get title bid back on track
- France's Auradou whistled on Pau return in Perpignan loss amid ongoing rape case
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Arsenal hit back in style after Southampton scare
- Thousands march for Palestinians ahead of Oct 7 anniversary
- Hezbollah heir apparent Safieddine out of contact after strikes
- Liverpool stay top of Premier League as Arsenal, Man City win
- In dank Tour of Emilia, Pogacar shines in rainbow jersey
- DR Congo launches mpox vaccination drive, hoping to curb outbreak
- Trump returns to site of failed assassination
- Careless Leverkusen held to Bundesliga draw
- O'Brien's 'superstar' Kyprios posts landmark win on Arc weekend
- Toddler crushed to death in migrant Channel crossing
- Liverpool suffer Alisson injury blow
- Habosi helps Racing beat Vannes before Auradou's playing return
- Thousands march in London in support of Palestinians, 1 year after Oct 7
- Israel readying response to Iran missile attack
- Schutt, Mooney help Australia beat Sri Lanka in Women's T20 World Cup
- Liverpool extend Premier League lead with win at Palace
- Djokovic 'shakes rust off' to make third round of Shanghai Masters
- 'Imperfect' PSG fighting on all fronts - Luis Enrique
- Struggling Pakistan look to thwart adaptable England
- Child 'trampled to death' in asylum seekers' Channel crossing: minister
Covid-flu joint booster jab possible late 2023: Moderna
Moderna aims to roll out a combined Covid-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm said Monday, hoping a joint jab would encourage people to get an annual shot.
The single vaccine for Covid-19, influenza and respiratory syncytial virus -- a common virus that causes the cold, but can be more serious for infants and elderly people -- could appear on the market before 2024.
"Best-case scenario will be the fall of '23," Moderna chief executive Stephane Bancel told a virtual World Economic Forum roundtable session.
"I don't think it would happen in every country, but we believe it's possible to happen in some countries next year.
"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter, but to get one dose."
- Trials in progress -
Bancel said the RSV programme was in Phase III trials -- the final stage of human testing -- while the flu programme should be entering Phase III in the second quarter of this year.
Moderna's experimental flu shot, targeting four major strains, is based on the same mRNA method used in its Covid-19 jabs.
The technology provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.
While Moderna's Covid-19 vaccine was based on the original strain of the virus, it was working on finishing an Omicron-specific jab within weeks, ahead of trials, said Bancel.
"We're hoping in the March timeframe we should be able to have data to share with regulators to figure out the next step forward."
- Hunt for 'holy grail' -
Beyond a vaccine specific to Omicron -- which is rapidly becoming the world's dominant strain -- laboratories are also pursuing a vaccine that works against all current and future Covid-19 mutations.
"There's some private sector partners that are pursuing it," said Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, which funds vaccine research and development.
"That would be the holy grail because we really don't want to be in position where we're chasing the new variants that are going to come.
"We don't want to be in a position where we're having to vaccinate everybody in the world every three or six months, or even annually, ideally."
Top US pandemic advisor Anthony Fauci added: "We really don't want to get into the whack-a-mole approach towards every new variant... because you'd be chasing it forever."
Bancel meanwhile said that Moderna had shipped 807 million doses of Covid-19 vaccine in 2021, of which a quarter went to middle- and low-income countries.
Thanks to extra capacity coming on stream before the end of March, the company hopes to be able to make two to three billion doses this year.
P.Stevenson--AMWN